PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 181 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Opinion: ‘Medical research charities are falling through the cracks of COVID-19... June 16, 2020 FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia September 3, 2021 The 10 Things That Helped Me Cope With My 2 Cancer... February 6, 2024 Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare... April 24, 2023 Load more HOT NEWS FDA Authorizes Blood Test for Assessing Risk of Hereditary Cancers Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical... COVID-19, Vaccines, and the Immune System: Emerging Research from NCI’s SeroNet Today is Giving Tuesday
